Progestins and oral contraceptive-induced lipoprotein changes: a prospective study

Area of Science:

• Endocrinology
• Cardiovascular Science
• Pharmacology

Background:

• Oral contraceptives (OCs) are widely used for birth control.
• Estrogenic and progestogenic components of OCs can influence lipid metabolism.
• Understanding the impact of varying progestin potency is crucial for cardiovascular risk assessment.

Purpose of the Study:

• To investigate the effects of oral contraceptives with identical ethinyl estradiol doses but varying progestin androgenic potency on plasma lipoproteins.
• To compare the lipoprotein profiles of women using different oral contraceptives with a control group using alternative contraception.

Main Methods:

• A prospective study involving 136 healthy women randomized into three groups.
• Each group received a different oral contraceptive formulation for one year.
• Lipoprotein levels were compared to a control group of 50 women using other contraceptive methods.

Main Results:

• All oral contraceptive groups showed increased plasma cholesterol (7-9%) and triglycerides (32-57%).
• The d-1 norgestrel (ENG) group exhibited significant increases in LDL-C (18%) and decreases in HDL-C (13%) and HDL2-C (27%).
• Apoprotein A-I increased with ethynodiol diacetate (EED) and norethindrone acetate (ENA) but not with ENG.

Conclusions:

• Oral contraceptives with the same estrogen but varying progestin androgenic potency induce distinct and significant changes in plasma lipoprotein profiles.
• Progestin choice in oral contraceptives plays a critical role in determining the extent and nature of lipoprotein alterations.
• These findings have implications for cardiovascular health management in women using oral contraceptives.